AstraZeneca invests $2 billion in Summit Therapeutics for 12% stake

• AstraZeneca agreed to invest USD 2 billion in newly issued equity in Summit Therapeutics to accelerate ivonescimab development.
• Purchase covers about 109,000 preferred shares convertible into common stock at a 1:1,000 ratio.
• Post-closing stake equals about 12.0% of Summit common stock outstanding, or about 10.6% on a fully diluted basis.
• Closing is expected within one week; any later conversion to common stock requires customary regulatory clearances.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on September 28, 2026, and is solely responsible for the information contained therein.